Nicole Pearsall, MD
Obstetrics & Gynecology · Omaha, NENPI 1518170737
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.
Across 177 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$514
- Astellas Pharma US Inc$491
- Sumitomo Pharma America, Inc.$425
- Bayer$313
- Mayne Pharma Commercial LLC$289
- Exeltis, USA Inc.$183
- plus $877 from 19 others
What the payments were for
- Food & beverage$2,81991%
- Education$2749%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $514 |
| Astellas Pharma US Inc | 17 | $491 |
| Sumitomo Pharma America, Inc. | 20 | $425 |
| Bayer | 17 | $313 |
| Mayne Pharma Commercial LLC | 24 | $289 |
| Exeltis, USA Inc. | 11 | $183 |
| Myovant Sciences Inc. | 7 | $119 |
| Organon | 6 | $115 |
| Pfizer | 8 | $106 |
| Therapeuticsmd, Inc. | 7 | $101 |
| Hologic Sales And Service, LLC | 4 | $62 |
| Coopersurgical, Inc. | 3 | $57 |
| Amgen | 3 | $50 |
| Daiichi Sankyo Inc. | 3 | $44 |
| Novo Nordisk | 2 | $36 |
| Agile Therapeutics, Inc. | 2 | $29 |
| Avion Pharmaceuticals | 2 | $29 |
| Baxter Healthcare | 1 | $18 |
| Minerva Surgical, Inc | 1 | $18 |
| Mylan Pharmaceuticals Inc. | 1 | $18 |
| Si-bone, Inc. | 1 | $17 |
| Evofem Biosciences, Inc. | 1 | $16 |
| Meditrina | 1 | $15 |
| Pelvital USA, Inc. | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
How this compares
$3,093 in reported general payments places this provider in the 85th percentile of 242 obstetrics & gynecology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alendronate Sodium | 17 | $149 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Omaha
- John CoteOmaha$236K
- Robin ClemmerOmaha$19K
- Susan UlmerOmaha$8K
- Jennifer CeraOmaha$5K
- Trevor WatsonOmaha$5K
- Jamie SeemanOmaha$4K
- Malorie HoweOmaha$4K
- Sonya TranOmaha$3K
- Jessica Prusa FloresOmaha$3K
- Tedette EllisOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.